Analyst consensus rating
Vivos Therapeutics Analyst Rating: none
Direct answer
Vivos Therapeutics's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $2.12.
Forecast evidence checked October 17, 2026.
Get free Vivos Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.13
- Average price target
- $2.12
- High price target
- $3.10
- Low price target
- $0.75
- Low target gap
- +472.1%
- Target upside
- +1,514.5%
- High target gap
- +2,264.6%
- Target range width
- 1,792.5%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Vivos Therapeutics?
Vivos Therapeutics has a verified none consensus. The same dataset has an average price target of $2.12.
How far are Vivos Therapeutics's low and high targets from the recorded price?
The low target implies +472.1%, while the high target implies +2,264.6%.
How many analysts are included in Vivos Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Vivos Therapeutics's target upside or downside calculated?
The average target of $2.12 is divided by the recorded price of $0.13, then one is subtracted to produce +1,514.5%. This does not guarantee a future return.
When was Vivos Therapeutics's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.